Patent issued February 23, 1971 Upjohn Company licensed July 1, 1973

Development programs began 4th quarter 1973

Pre-NDA report on 25-OHD, in renal disease made to FDA in 1976; additional data requested causing delay in meeting until February 1978

meeting until February 1978

NDA for 25-OHD, in renal disease filed with FDA on May 14, 1979

Calderol approved for use in treatment of metabolic bone disease in dialysis patients on August 5, 1980

Marketing began October 1980

### Summary

February 1971 Patent issued 5 months July 1973 - 2 years Patent licensed May 1979 - 5 years 10 months NDA filed 3 months August 1980 - 1 year FDA approval October 1980 -2 months Marketing began 9 years 8 months 4 months Remaining Patent life 7 years Total 17 years

Patent issued February 23, 1971 Upjohn Company licensed July 1, 1973

Development programs began 4th quarter 1973
Pre-NDA report on 25-OHD<sub>3</sub> in renal disease made to FDA in 1976; additional data requested causing delay in

meeting until February 1978

NDA for 25-OHD, in renal disease filed with FDA on May 14, 1979

Calderol B approved for use in treatment of metabolic bone disease in dialysis patients on August 5, 1980

Marketing began October 1980

### Summary

Patent issued	February 1971		
Patent licensed	July 1973	- 2 years	5 months
NDA filed	May 1979	- 5 years	10 months
FDA approval	August 1980	- 1 year	3 months
Marketing began	October 1980	~ <u> </u>	2 months
		9 years	8 months
Remaining Patent life		7 years	4 months
	·		

Patent issued February 23, 1971

Upjohn Company licensed July 1, 1973

Development programs began 4th quarter 1973

Pre-NDA report on 25-OHD, in renal disease made to FDA in 1976; additional data requested causing delay in meeting until February 1978

NDA for 25-OHD, in renal disease filed with FDA on May 14, 1979

Calderol B approved for use in treatment of metabolic bone disease in dialysis nations on August 5, 1990 in dialysis patients on August 5, 1980

Marketing began October 1980

### Summary

February 1971 Patent issued - 2 years 5 months Patent licensed July 1973 NDA filed May 1979 - 5 years 10 months - 1 year 3 months August 1980 FDA approval October 1980 -2 months Marketing began 8 months 9 years 4 months Remaining Patent life 7 years Total 17 years

Patent issued February 23, 1971

Upjohn Company licensed July 1, 1973

Development programs began 4th quarter 1973
Pre-NDA report on 25-OHD, in renal disease made to FDA in 1976; additional data requested causing delay in

meeting until February 1978

NDA for 25-OHD, in renal disease filed with FDA on May 14, 1979

Calderol Papproved for use in treatment of metabolic bone disease in dialysis patients on August 5, 1980

Marketing began October 1980

## Summary

February 1971 Patent issued - 2 years 5 months July 1973 Patent licensed May 1979 - 5 years 10 months NDA filed 3 months August 1980 - 1 year FDA approval 2 months Marketing began October 1980 👉 '9 years 8 months 4 months Remaining Patent life 7 years Total 17 years